A promising new strategy for malaria drug development

Malaria kills over 600,000 people a year, and as the climate warms, the potential range of the disease is growing. While some drugs can effectively prevent and treat malaria, resistance to those drugs is also on the rise.

Lobe Sciences Initiates Phase 1 Clinical Trial of L-130 | Psychedelic Invest

Lobe Sciences Ltd. (OTCQB: LOBEF / CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the initiation of

June 27, 2023

Digital health funding flattens out, PitchBook report shows

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 27, 2024

Netflix for Healthcare: Direct Primary Care & Shared Decision-Making

Dr. Jacob DeWitt, MD, UHSM Ambassador and Founder, Integrative Direct Primary Care In an era when healthcare costs continue to soar, a deviation from the

February 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.